Conference Series LLC Ltd. welcomes you to attend the Annual Summit on Cell Therapy and Molecular Medicine during September 27-28, 2017 at Chicago, Illinois, USA. We cordially invite all the participants from all over the world who are interested in sharing their knowledge and research in the area of Cell Therapy and Molecular Medicine. The theme of Annual Summit on Cell Therapy and Molecular Medicine is "Latest Innovations and Advancements in Cell & Gene Therapies to Alleviate Human Diseases" which provides a unique way to present the evidences on latest advancements and researches with a holistic approach to different areas of interest. The conference tracks are designed in such a way so as to cover all the areas of researches involved with Cell Therapy and Molecular Medicine and their impacts on human health. The main aim of this conference is to provide a platform to all the scientists, doctors, medical professionals and business delegates who will undoubtedly enhance the conference by giving their views regarding recent breakthroughs to all the attendees. 

Cell Therapy and Molecular Medicine Conference is to elevate the knowledge, awareness, and education on cell therapy, gene therapy, molecular medicine and stem cell research leading to the discovery of molecular therapies which aids to alleviate the human diseases as it is the most significant emerging technology in the eyes of medical, biotechnology, pharmaceuticals and academia. This two-day Cell Therapy and Molecular Medicine Event will address key issues concerning cell therapy, gene therapy and molecular medicine in the broader context of cellular and genetic disorder. Organized around daily themes, this conference focuses on moving from present knowledge to future solutions thus imparting the knowledge growth and awareness among people.

About Organizer

Conference Series LLC Ltd. Organises 300+ International Conferences Every Year across Europe, USA and Asia with support from 1000 more scientific Societies and Publishes 400+ Open access journals which contains over 30000 eminent personalities, reputed scientists as Editorial Board Members. Now it is the time for the 2^nd Annual Summit on Cell Therapy and Stem Cell Research during November 9-10, 2017 at Atlanta, USA. 

Target Audience

Cell Therapy Scientists, Researchers and Students

Molecular Medicine Scientists, Researchers and Students

Biotechnologists

Immunologists

Health-care professionals

Gene therapy Researchers, Scientists and Students

Cell and Gene therapy Faculties

Cell and Gene Therapy Associations and Societies

Universities and College students

Allied health professionals in the fields of cell and gene therapy, haematology, oncology, neurology, family medicine and internal medicine.

Stem Cell Students, Scientists

Stem Cell Researchers and Faculty

Stem Cell Associations and Societies

Business Entrepreneurs

Training Institutes

Software developing companies

This conference also includes Symposium, Key note presentations, Oral presentations, B2B meetings, Poster presentations and Exhibitions. Moreover, Cell Therapy and Molecular Medicine 2017 welcomes international exhibition from corporate sectors to advertise their products/services from recent advancements that shall be placed in the exhibition area throughout the conference. 

Track 1: Cell Therapy

Cell therapy or cytotherapy is the transfer of cells into a patient with a goal of improving the disease.  From beginning blood transfusions were considered to be the first type of cell therapy to be practised as routine. Later, Bone marrow transplantation has also become a well established concept which involves treatment of many kind of blood disorders including anemia, leukemia, lymphyoma and rare immunodeficiency diseases. Alternative medical practitioners perform cell therapy in the form of several different names including xenotransplant therapy, glandular therapy, and fresh cell therapy. It has been claimed by the proponents of cell therapy that it has been used successfully to repair spinal cord injuries, strengthen weaken immune system, treats autoimmune diseases like AIDS, help patients with neurological disorders like Alzheimer’s disease, parkinson’s disease and epilepsy. 

Related Conferences

3rd International Conference & Exhibition on Tissue Preservation and Biobanking, Aug 23-24 2017, San Francisco, USA; Annual Summit on Cell Signaling and Cancer Therapy, Sep 27-28, 2017, Chicago, USA; 8^th World Congress and Expo on Cell & Stem Cell Research, March 20-22, 2017 in Orlando, Florida, USA; Annual Summit on Cell Therapy and Molecular Medicine, Sep 27-28, 2017, Chicago, USA; 2nd World Biotechnology Congress, Dec 4-5 2017, Sao Paulo, Brazil; Spring Symposium of the Netherlands Society of Gene & Cell therapy (NVGCT), 17 March 2017, Lunteren, The Netherlands; British Society for Gene and Cell Therapy (BSGCT) Public Engagement 2017, March 27-28, 2017 Oxford, UK; 19^th International Conference on Cell and Gene Therapy – ICCGT 2017, April 19-21, 2017, Singapore; International Society for BioProcess Technology 7^th Spring Meeting – Viral vectors and vaccines, March 16-17, 2017, Washington, DC and 2^nd Annual Genome Editing & Engineering Conference, Feb 6-7 2017, San Diego, CA.  

Track 2: Gene Therapy

Gene therapy basically involves the introduction or alteration of genetic material within a cell  or organism with an intention of curing the disease. Both cell therapy and gene therapy are overlapping fields of biomedical  research with the goals of repairing the direct cause of genetic diseases in DNA or cellular population respectively. The discovery of recombinant DNA technology in the 1970s provided tools to efficiently develop gene therapy. Scientists use these techniques to readily manipulate viral genomes, isolate genes and identify mutations involved in human disease, characterize and regulate gene expressions, and engineer various viral and non viral vectors. Various long term treatments for anemia, haemophilia, cystic fibrosis, muscular dystrophy, Gauscher’s disease, lysosomal storage diseases, cardiovascular diseases, diabetes and diseases of bones and joints are resolved through successful gene therapy and are elusive today. 

Related Conferences

Annual Summit on Cell Signaling and Cancer Therapy, Sep 27-28, 2017, Chicago, USA; Annual Summit on Cell Therapy and Molecular Medicine, Sep 27-28, 2017, Chicago, USA; 2nd World Biotechnology Congress, Dec 4-5 2017, Sao Paulo, Brazil; 3rd International Conference & Exhibition on Tissue Preservation and Biobanking, Aug 23-24 2017, San Francisco, USA; 8^th World Congress and Expo on Cell & Stem Cell Research, March 20-22, 2017, Orlando, Florida, USA; 10^th Australasian Gene Therapy Society Meeting (AGCTS), October 17-20, 2017, Sydney, Australia; XXV Congress of the European Society of Gene and Cell Therapy (ESGCT), Berlin, Germany.

Track 3: Molecular Medicine

Molecular Medicine is a branch of medicine that develops ways to diagnose and treat diseases by understanding the ways genes, proteins and other cellular molecules work. It is a broad field where physical, chemical, biological, bioinformatics, and medical techniques are used to describe molecular structures and mechanisms, identify fundamental molecular and genetic errors of the disease, and to develop molecular interventions to correct them.  Molecular Medicine has now a days proved to be an exciting field of research as some of the recent advancements has led to improved clinical benefits for human health. These are LPS- induced inflammatory response is suppressed by Wnt inhibitors, Dickkopf-1 and LGK974, Selective inhibition of Ebola entry with selective estrogen receptor modulators by disrupting the endolysosomal calcium, ApoA-IV improves insulin sensitivity and glucose uptake in mouse adipocytes via PI3K-Akt Signalling and many more.   

Related Conferences

Annual Summit on Cell Therapy and Molecular Medicine, Sep 27-28, 2017, Chicago, USA; 2nd World Biotechnology Congress, Dec 4-5 2017, Sao Paulo, Brazil; 3rd International Conference & Exhibition on Tissue Preservation and Biobanking, Aug 23-24 2017, San Francisco, USA; Annual Summit on Cell Signaling and Cancer Therapy, Sep 27-28, 2017, Chicago , USA; 8^th World Congress and Expo on Cell & Stem Cell Research, March 20-22, 2017, Orlando, Florida, USA; Annual  conference of British Society for Gene and Cell Therapy (BSGCT), May 3-6, 2017, Cardiff, Wales, UK; International Society for Cellular Therapy (ISCT) 23^rd Annual Meeting, May 10-13, 2017, London, UK; American Society of Gene and Cell Therapy (ASGCT) 20^th Annual Meeting , May 14-19, 2017, Washington, DC; Gordon Research Conference: Viruses & Cells, May 17-19, 2017, Lucca, Italy and World Advanced Therapies and Regenerative Medicine Congress 2017, May 24-26, 2017, London, UK.

Track 4: Immunotherapy 

Due to rapidly advancing field of cancer immunology in past few years, there has been production of several new methods of treating cancer called Immunotherapies. Immunotherapy is a type of treatment that increases the strength of immune response against tumors either by stimulating the activities of specific components of immune system or by counteracting signals produced by cancer cells that suppress immune responses. Some types of immunotherapy are also called as biologic therapy or biotherapy. Recent advancements in cancer immunotherapies have provided new therapeutic approaches. These include tumor-associated macrophages as treatment targets in oncology, in-situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy, immune checkpoint blockade and associated endocrinopathies and many more. 

Related Conferences

3rd International Conference & Exhibition on Tissue Preservation and Biobanking, Aug 23-24 2017, San Francisco, USA; Annual Summit on Cell Signaling and Cancer Therapy, Sep 27-28, 2017, Chicago, USA; 8^th World Congress and Expo on Cell & Stem Cell Research, March 20-22, 2017 in Orlando, Florida, USA; Annual Summit on Cell Therapy and Molecular Medicine, Sep 27-28, 2017, Chicago, USA; 2nd World Biotechnology Congress, Dec 4-5 2017, Sao Paulo, Brazil; Spring Symposium of the Netherlands Society of Gene & Cell therapy (NVGCT), 17 March 2017, Lunteren, The Netherlands; British Society for Gene and Cell Therapy (BSGCT) Public Engagement 2017, March 27-28, 2017 Oxford, UK; 19^th International Conference on Cell and Gene Therapy – ICCGT 2017, April 19-21, 2017, Singapore; International Society for BioProcess Technology 7^th Spring Meeting – Viral vectors and vaccines, March 16-17, 2017, Washington, DC and 2^nd Annual Genome Editing & Engineering Conference, Feb 6-7 2017, San Diego, CA.  

Genetic Medicine or Medical Genetics is the branch of medicine that differs from human genetics, and involves the diagnosis and management of hereditary disorders. Human genetics may or may not apply to medicine, but medical genetics refers to the application of genetics to medical care. Genetic Medicine basically involves different areas such as gene therapy, personalized medicine, predictive medicine and the rapidly emerging new medical specialty. Now a days, medical genetics has wide range of scopes in many conditions involving birth defects and dysmorphology, autism, mental retardation, skeletal dysplasia, mitochondrial disorders, cancer genetics, connective tissue disorders and some more.  

Related Conferences

Annual Summit on Cell Signaling and Cancer Therapy, Sep 27-28, 2017, Chicago, USA; Annual Summit on Cell Therapy and Molecular Medicine, Sep 27-28, 2017, Chicago, USA; 2nd World Biotechnology Congress, Dec 4-5 2017, Sao Paulo, Brazil; 3rd International Conference & Exhibition on Tissue Preservation and Biobanking, Aug 23-24 2017, San Francisco, USA; 8^th World Congress and Expo on Cell & Stem Cell Research, March 20-22, 2017, Orlando, Florida, USA; 10^th Australasian Gene Therapy Society Meeting (AGCTS), October 17-20, 2017, Sydney, Australia; XXV Congress of the European Society of Gene and Cell Therapy (ESGCT), Berlin, Germany. 

Track 6: Clinical Trials in Cell and Gene Therapy

A clinical trial is a research study that tests how well new medical approaches work on people and determines if a treatment is safe and effective. The new cell and gene therapies (CGTs) that are advancing from the laboratory into early phase clinical trials has proven to be a complex task even for experienced investigators . As a result of wide variety of CGT products and their potential applications, a case by case assessment is warranted for the design of each clinical trial. Some of the latest and advanced clinical trials include safety and efficacy trial of AAV gene therapy in patients with CNGA3 Achromatopsia, A clinical trial for treatment of Aromatic L- Amino acid Decarboxylase (AADC) deficiency using AAV2-hAADC- An expansion and Glypican 3-specific Chimeric antigenic receptor expressed in T cells for patients with pediatric solid tumors. 

Related Conferences

Annual Summit on Cell Therapy and Molecular Medicine, Sep 27-28, 2017, Chicago, USA; 2nd World Biotechnology Congress, Dec 4-5 2017, Sao Paulo, Brazil; 3rd International Conference & Exhibition on Tissue Preservation and Biobanking, Aug 23-24 2017, San Francisco, USA; Annual Summit on Cell Signaling and Cancer Therapy, Sep 27-28, 2017, Chicago , USA; 8^th World Congress and Expo on Cell & Stem Cell Research, March 20-22, 2017, Orlando, Florida, USA; Annual  conference of British Society for Gene and Cell Therapy (BSGCT), May 3-6, 2017, Cardiff, Wales, UK; International Society for Cellular Therapy (ISCT) 23^rd Annual Meeting, May 10-13, 2017, London, UK; American Society of Gene and Cell Therapy (ASGCT) 20^th Annual Meeting , May 14-19, 2017, Washington, DC; Gordon Research Conference: Viruses & Cells, May 17-19, 2017, Lucca, Italy and World Advanced Therapies and Regenerative Medicine Congress 2017, May 24-26, 2017, London, UK.

Track 7: Cell Therapy Bioprocessing

Cell Therapy Bioprocessing activity mainly focuses to accelerate the safe, cost- effective translations and clinical efficacious of cell therapies into commercial products. This activity covers the entire range of cell therapy activities as well as tissue engineering. In order to succeed, commercial success of at least a few late-stage products are required to develop which will be funded to develop next generation tools and technologies for this field. Recent achievements include, preclinical filing for Phase 1 clinical trials for cell therapy in acute spinal cord injury, clinical proof of concept studies in tissue- engineered trachea, clinical trials for tissue-engineered larynx and routine clinical practice in the regeneration of corneas. The future research priorities will focus on novel cell and bioprocess engineering techniques in order to improve the manufacturing efficacy and methods for health technology assessment to support rapid clinical adoption of new cell therapies.  

Related Conferences 

3rd International Conference & Exhibition on Tissue Preservation and Biobanking, Aug 23-24 2017, San Francisco, USA; Annual Summit on Cell Signaling and Cancer Therapy, Sep 27-28, 2017, Chicago, USA; 8^th World Congress and Expo on Cell & Stem Cell Research, March 20-22, 2017 in Orlando, Florida, USA; Annual Summit on Cell Therapy and Molecular Medicine, Sep 27-28, 2017, Chicago, USA; 2nd World Biotechnology Congress, Dec 4-5 2017, Sao Paulo, Brazil; Spring Symposium of the Netherlands Society of Gene & Cell therapy (NVGCT), 17 March 2017, Lunteren, The Netherlands; British Society for Gene and Cell Therapy (BSGCT) Public Engagement 2017, March 27-28, 2017 Oxford, UK; 19^th International Conference on Cell and Gene Therapy – ICCGT 2017, April 19-21, 2017, Singapore; International Society for BioProcess Technology 7^th Spring Meeting – Viral vectors and vaccines, March 16-17, 2017, Washington, DC and 2^nd Annual Genome Editing & Engineering Conference, Feb 6-7 2017, San Diego, CA.  

Cell  and Gene Therapy products manufacturing focuses on various strategies like the manufacturing process must protect the product, patient, should focus on product characterization, process control, high throughput and parallel processing to achieve scale. The process/analytical development throughout clinical trials involve ongoing, iterative development of manufacturing process and characterization of profile and FDA expecting increasing control and characterization as clinical development progresses. Steps involved in individualized manufacturing and running in parallel for high throughput involves cell selection, expansion, activation, centrifugation and cryopreservation. 

Related Conferences

Annual Summit on Cell Signaling and Cancer Therapy, Sep 27-28, 2017, Chicago, USA; Annual Summit on Cell Therapy and Molecular Medicine, Sep 27-28, 2017, Chicago, USA; 2nd World Biotechnology Congress, Dec 4-5 2017, Sao Paulo, Brazil; 3rd International Conference & Exhibition on Tissue Preservation and Biobanking, Aug 23-24 2017, San Francisco, USA; 8^th World Congress and Expo on Cell & Stem Cell Research, March 20-22, 2017, Orlando, Florida, USA; 10^th Australasian Gene Therapy Society Meeting (AGCTS), October 17-20, 2017, Sydney, Australia; XXV Congress of the European Society of Gene and Cell Therapy (ESGCT), Berlin, Germany.

Track 9: Rare Diseases & Orphan drugs

Rare diseases are life-threatening or chronically debilitating conditions, affecting no more than 5 in 10,000 persons in the European Community according to the Regulation (EC) N. 141/2000 of the European Parliament and of the Council. It is estimated that between 6000 to 8000 distinct rare diseases affect up to 6% of the total EU population. Therefore, these conditions can be considered rare if taken individually but they affect a significant proportion of the European population when considered as a single group. Several initiatives have been taken at international, European and national level to tackle public health as well as research issues related to diagnosis, prevention, treatment and surveillance of these diseases. An Orphan drug can be defined as the one that is used to treat an orphan disease. An orphan disease in USA is defined as the one that affects fewer than 200000 individuals, but in Japan the number is 50,000 and in Australia is 2000. In past 20 years efforts have been made to encourage companies to develop orphan drugs. The Orphan Drug Act in the USA (1983) was succeeded by similar legislation in Japan (1985), Australia (1997), and the European Community (2000). The encouragement takes three forms: tax credits and research aids, simplification of marketing authorization procedures, and extended market exclusively. 

Related Conferences 

Annual Summit on Cell Therapy and Molecular Medicine, Sep 27-28, 2017, Chicago, USA; 2nd World Biotechnology Congress, Dec 4-5 2017, Sao Paulo, Brazil; 3rd International Conference & Exhibition on Tissue Preservation and Biobanking, Aug 23-24 2017, San Francisco, USA; Annual Summit on Cell Signaling and Cancer Therapy, Sep 27-28, 2017, Chicago, USA; 8^th World Congress and Expo on Cell & Stem Cell Research, March 20-22, 2017, Orlando, Florida, USA; Annual  conference of British Society for Gene and Cell Therapy (BSGCT), May 3-6, 2017, Cardiff, Wales, UK; International Society for Cellular Therapy (ISCT) 23^rd Annual Meeting, May 10-13, 2017, London, UK; American Society of Gene and Cell Therapy (ASGCT) 20^th Annual Meeting , May 14-19, 2017, Washington, DC; Gordon Research Conference: Viruses & Cells, May 17-19, 2017, Lucca, Italy and World Advanced Therapies and Regenerative Medicine Congress 2017, May 24-26, 2017, London, UK. 

Stem cells can self renew themselves and differentiate or develop into more specialised cells. They are the foundation for every organ and tissue in our body.  Due to this ability of the stem cells, they have tremendous promise to help us understand and treat a wide range of diseases, injuries and other health related problems. Bone marrow transplantation is the most widely used stem cell therapy , but some of the therapies are derived from umbilical cord blood are also in use today. Likewise, blood stem cells are used to treat diseases of blood, a therapy that has saved thousands of lives of children with leukemia. Some bone, skin and corneal (eye) injuries and diseases can be treated by grafting or implanting tissues and the healing process relies on stem cells with implanted tissue. Regenerative medicines aims to replace tissues or organs that have been damaged by disease, trauma, or congenital issues which is in contrast to the current clinical strategy that focuses primarily on treating the symptoms. These regenerative medicines have wide appropriateness in treating degenerative scatters including dermatology, cardio vascular, and neuro degenerative diseases. Cell treatment is the quickest developing fragment of regenerative drug and this undeveloped cell treatment is making up the biggest part of this business sector.   

Related Conferences 

3rd International Conference & Exhibition on Tissue Preservation and Biobanking, Aug 23-24 2017, San Francisco, USA; Annual Summit on Cell Signaling and Cancer Therapy, Sep 27-28, 2017, Chicago, USA; 8^th World Congress and Expo on Cell & Stem Cell Research, March 20-22, 2017 in Orlando, Florida, USA; Annual Summit on Cell Therapy and Molecular Medicine, Sep 27-28, 2017, Chicago, USA; 2nd World Biotechnology Congress, Dec 4-5 2017, Sao Paulo, Brazil; Spring Symposium of the Netherlands Society of Gene & Cell therapy (NVGCT), 17 March 2017, Lunteren, The Netherlands; British Society for Gene and Cell Therapy (BSGCT) Public Engagement 2017, March 27-28, 2017 Oxford, UK; 19^th International Conference on Cell and Gene Therapy – ICCGT 2017, April 19-21, 2017, Singapore; International Society for BioProcess Technology 7^th Spring Meeting – Viral vectors and vaccines, March 16-17, 2017, Washington, DC and 2^nd Annual Genome Editing & Engineering Conference, Feb 6-7 2017, San Diego, CA.  

Cancer is a process where the cells grow aberrantly and this growth of cancer cells results in damage of normal tissues, causing loss of function and often pain. The cancer therapeutic drugs are those drugs that block the growth and spread of cancer by interfering with specific molecules (molecular targets) that are involved in the growth, progression and spread of cancer. Moreover, gene therapy  approaches may be designed to directly kill tumor cells using tumor killing viruses, or through the introduction of genes termed as suicide genes into the tumor cells. The Food and Drug Administration (FDA) has approved many cancer therapies in order to treat specific types of cancers. To develop targeted therapies it requires the identification of good targets that is, those targets that play a key role in cancer cell growth and survival.  One way to identify potential targets is to compare the amounts of individual proteins in cancer cells with those present in normal cells. Gene silencing has also been designed to inhibit the expression of specific genes which are activated or over expressed in cancer cells and can drive tumor growth, blood vessel formation and allow resistance for chemotherapy. 

Related Conferences 

Annual Summit on Cell Signaling and Cancer Therapy, Sep 27-28, 2017, Chicago, USA; Annual Summit Summit on Cell Therapy and Molecular Medicine, Sep 27-28, 2017, Chicago, USA; 2nd World Biotechnology Congress, Dec 4-5 2017, Sao Paulo, Brazil; 3rd International Conference & Exhibition on Tissue Preservation and Biobanking, Aug 23-24 2017, San Francisco, USA; 8^th World Congress and Expo on Cell & Stem Cell Research, March 20-22, 2017, Orlando, Florida, USA; 10^th Australasian Gene Therapy Society Meeting (AGCTS), October 17-20, 2017, Sydney, Australia; XXV Congress of the European Society of Gene and Cell Therapy (ESGCT), Berlin, Germany.

Track 12: Nuclear Medicine

Nuclear medicine is a branch of medical imaging that involves the application of radioactive substances called radiotracers that are generally injected into the bloodstream, inhaled or swallowed. The radiotracer then travels through the area being examined and gives off energy in the form of gamma rays, which are detected by a special camera and a computer to create images of inside the body. It is used to diagnose or determine the severity of or treat different types of diseases like many types of cancers, heart disease, neurological disease, gastrointestinal disease, and other abnormalities inside the body. As nuclear medicine techniques are able to identify molecular activity within the body, they offer the capability to detect diseases in its very early stages as well as a patient’s immediate response to therapeutic interventions. There are two most common imaging methods in nuclear medicine, one is Single Photon Emission Computed Tomography or SPECT and the other is Positron Emission Tomography or PET scans.  

Related Conferences 

Annual Summit on Cell Therapy and Molecular Medicine, Sep 27-28, 2017, Chicago, USA; 2nd World Biotechnology Congress, Dec 4-5 2017, Sao Paulo, Brazil; 3rd International Conference & Exhibition on Tissue Preservation and Biobanking, Aug 23-24 2017, San Francisco, USA; Annual Summit on Cell Signaling and Cancer Therapy, Sep 27-28, 2017, Chicago , USA; 8^th World Congress and Expo on Cell & Stem Cell Research, March 20-22, 2017, Orlando, Florida, USA; Annual  conference of British Society for Gene and Cell Therapy (BSGCT), May 3-6, 2017, Cardiff, Wales, UK; International Society for Cellular Therapy (ISCT) 23^rd Annual Meeting, May 10-13, 2017, London, UK; American Society of Gene and Cell Therapy (ASGCT) 20^th Annual Meeting , May 14-19, 2017, Washington, DC; Gordon Research Conference: Viruses & Cells, May 17-19, 2017, Lucca, Italy and World Advanced Therapies and Regenerative Medicine Congress 2017, May 24-26, 2017, London, UK.

 Track 13: Advances in Cell Engineering, Imaging and Screening

In recent times, advancements in cell engineering, imaging and screening has reached a great height in the field of science & technology and also in the business world. It has attracted many scientists from academia and also established or emerging companies in the field to present their latest scientific achievements and exciting technological solutions through presentations in several sessions. This has helped in improving the scientific knowledge among the people, scientists, researchers and exhibitors from all over the world thus enhancing their scientific curiosity and providing robust solutions against technological issues. 

Related Conferences

3rd International Conference & Exhibition on Tissue Preservation and Biobanking, Aug 23-24 2017, San Francisco, USA; Annual Summit on Cell Signaling and Cancer Therapy, Sep 27-28, 2017, Chicago, USA; 8^th World Congress and Expo on Cell & Stem Cell Research, March 20-22, 2017 in Orlando, Florida, USA; Annual Summit on Cell Therapy and Molecular Medicine, Sep 27-28, 2017, Chicago, USA; 2nd World Biotechnology Congress, Dec 4-5 2017, Sao Paulo, Brazil; Spring Symposium of the Netherlands Society of Gene & Cell therapy (NVGCT), 17 March 2017, Lunteren, The Netherlands; British Society for Gene and Cell Therapy (BSGCT) Public Engagement 2017, March 27-28, 2017 Oxford, UK; 19^th International Conference on Cell and Gene Therapy – ICCGT 2017, April 19-21, 2017, Singapore; International Society for BioProcess Technology 7^th Spring Meeting – Viral vectors and vaccines, March 16-17, 2017, Washington, DC and 2^nd Annual Genome Editing & Engineering Conference, Feb 6-7 2017, San Diego, CA.

Track 14: Synthetic Biology and Genetic modifications of cells

Synthetic Biology is one of the emerging field of research that can be broadly described as the design and construction of novel artificial biological pathways, organisms or devices or the redesigning of existing natural biological systems. Genome editing  with engineered nucleases is a type of genetic engineering in which DNA is either inserted, replaced or deleted in the genome of an organism using engineered nucleases or “molecular scissors”. These nucleases hence create site specific double stranded breaks (DSBs) at desired locations in the genome. The induced double stranded breaks are repaired through non homologous end- joining (NHEJ) or homologous recombination (HR), thus resulting in targeted mutations (edits”). Scientists now a days use various engineered nucleases in order to bring desired changes in the human genome.   

Related Conferences 

Annual Summit on Cell Signaling and Cancer Therapy, Sep 27-28, 2017, Chicago, USA; Annual Summit Summit on Cell Therapy and Molecular Medicine, Sep 27-28, 2017, Chicago, USA; 2nd World Biotechnology Congress, Dec 4-5 2017, Sao Paulo, Brazil; 3rd International Conference & Exhibition on Tissue Preservation and Biobanking, Aug 23-24 2017, San Francisco, USA; 8^th World Congress and Expo on Cell & Stem Cell Research, March 20-22, 2017, Orlando, Florida, USA; 10^th Australasian Gene Therapy Society Meeting (AGCTS), October 17-20, 2017, Sydney, Australia; XXV Congress of the European Society of Gene and Cell Therapy (ESGCT), Berlin, Germany. 

Importance and Scope of Cell Therapy & Molecular Medicine:-

Cell Therapy describes about the administration of live whole cells or maturation of a specific cell population in a patient for treatment of a disease. In recent times, cell therapy is expanding its range of cell types for administration. Various treatment strategies of cell therapy include, isolation and transfer of specific stem cell populations, administration of effector cells, induction of mature cells to become pluripotent cells, and reprogramming of mature cells. By administrating a large number of effector cells has benefited a large number of cancer patients, transplant patients with unresolved infections, and patients with chemically destroyed stem cells in eyes. Gene therapy on the other hand is expressed as an experimental treatment that involves introduction of genetic material into the cells in order to correct the defective genes. Retroviruses and adenoviruses are among the most commonly used viral vectors in trials for treating diseases under gene therapy. Other viral vectors such as adeno-associated viruses, pseudotyped viruses and herpes simplex viruses are also gaining popularity. Some proposed non viral vectors for gene transfer include physical methods and the employment of chemical vectors like lipoplexes, polyplexes and inorganic nanoparticles. Several diseases benefit from both cell and gene therapies. For example, some patients have a severe combined immunodeficiency disease (SCID) but unfortunately do not have a suitable donor of the bone marrow. Several dozen of patients have been treated with both combined cell and gene therapy approach. More evidence for wider clinical applications for both cell and gene therapy are expected as more cell and gene therapy studies progress from preclinical phase to clinical trial. Molecular Medicine is one of an important application in the field of bioinformatics research. Due to the fact that complete sequencing of human genome has enabled to improve the biological reserach and clinical medicine, scientists can now find cures against diseases either heriditary or acquired. Therefore, it will enable the pharmaceutical industry to design drugs which will only target those genes which are defective.  

Why Chicago?

As both cell and gene therapy has gained many applauds from all over the world, and due to this reason these therapies are given much more importance from the beginning of their inceptions. Cell and Gene therapies both are well performed worldwide in order to treat many types of diseases like SCID, Cancer, Cardiovascular diseases Type 1 diabetes and many more. In spite of many legal and ethical issues these therapies are now accepted worldwide but still faces many challenges in some countries and this is the reason that many people are still today out of reach of their benefits especially on human health. According to ClinicalTrials.gov, USA has conducted maximum number of studies (2,740) among other countries which shows a huge scope for promoting the benefits of both cell and gene therapy by the scientists, researchers and clinical industries to treat many diseases which do not have a proper treatment till date. Gene therapy products have not been currently approved by US FDA and therefore gene therapy products are still in the investigational stage. Some of the promising treatments that are not yet licensed are mainly available through a clinical trial. As many recent researches have been conducted in USA on human diseases by using different animal models, hence it has resulted in development of new technologies, new therapies and showed exciting improvements in disease treatments. Therefore positive hopes lies with these therapies in future also in spite of failures and non-approval. Advancements in cell and gene therapy products in USA are just a step away.  

Societies associated with Cell Therapies:-

•    Adult Stem Cell Research Network
•   Alzheimer’s Cure Foundation
•   American Academy of Anti-Ageing Medicine (A4m)
•   American Association for Cancer Research (AACR)
•   American Cancer Society
•   American Society for Cell Biology
•   American Society for Investigating Pathology
•   American Society Radiation Oncology
•   Cell Therapy Foundation
•   European Society of Gene and Cell Therapy

Societies associated with Gene Therapies:-

Market Research on Cell Therapy:-

The market of cell therapy in terms of revenues is $3 billion and the annual growth rate from 2011- 2016 is 28.4%. The market of stem cell therapy is poised to grow at a CAGR of 39.5% from 2015 to 2020., to reach $330 million by 2020. The global stem cell therapy market on the basis of the mode of treatment is segmented into allogenic and autologous stem cell therapy.

Market Research on Gene Therapy:-

The gene therapy market in spite of presenting few marketable products and being nascent in terms of revenue generation holds tremendous growth potential. As per a new estimation carried out in a latest study, the global gene therapy industry has the potential to become a multi-million dollar industry by the end of 2017 as new products, especially those in the advanced stage of clinical studies or with pending approvals, may enter the market to boost the growth.